Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16520058 | 0.82 | SSTR4 (0.49) | GPR119PIK3CASSTR4 | |
| SCHEMBL16520051 | 0.81 | SSTR4 (0.52) | GPR119PIK3CASSTR4 | |
| SCHEMBL6899304 | 0.80 | SSTR4 (0.51) | GPR119PIK3CASSTR4 | |
| SCHEMBL20120962 | 0.79 | GPR119 (0.64) | GPR119 | |
| SCHEMBL20120507 | 0.79 | GPR119 (0.64) | GPR119 | |
| SCHEMBL29547496 | 0.79 | GPR119 (0.64) | GPR119 | |
| SCHEMBL28628163 | 0.79 | PIK3CD (0.50) | GPR119PIK3CAPIK3CD | |
| SCHEMBL16520108 | 0.79 | SSTR4 (0.48) | GPR119PIK3CASSTR4PIK3CD | |
| SCHEMBL16520144 | 0.79 | SSTR4 (0.48) | GPR119PIK3CASSTR4PIK3CD | |
| SCHEMBL16759365 | 0.78 | NPBWR1 (0.49) | GPR119PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | GPR119 3791/4885PIK3CA 2277/4885SSTR4 4723/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | GPR119 3741/4885PIK3CA 2528/4885SSTR4 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.